- Home
- Pathology Industry
- Celgene Market and Forecasts, May 2013
Industries
- Pathology (13)
- Drug and Medication (12)
- Biological Therapy (6)
- Managed Care (4)
- Biopharmaceutical (3)
-
- Biotechnology (3)
- Drug Discovery and Development (3)
- Metal and Mineral (3)
- Pharmaceutical (3)
- Healthcare (2)
- Investment Banking (2)
- Water Distribution and Treatment (2)
- Diagnostics (1)
- Drug Delivery Technology (1)
- Home and Office Goods (1)
- Medical Equipment and Supply (1)
- Nanotechnology (1)
- Road Passenger Transport (1)
- Video Game (1)
Top countries
Publication dates
All regions
data types
- All
- Company Data (919)
- Industry Data
- Country Data (54)
Celgene Market and Forecasts, May 2013
You might be interested in: cancer, clinical trial, drug, more »
industry reports
country reports
» Download Public Reports
1-10 of 62 reports for Celgene
Water Business in The United States and Switzerland
- Industry report
- January 2011
- 22 pages
... Worldwide. At celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing ...
- Industries: Water Distribution and Treatment
- Countries: United States, Switzerland
U.S. Pharmaceutical Industry Brief
- Industry report
- January 2011
- 2 pages
... Physicians to prescribe rev- limid to patients who have already tried other treatments. The drug accounts for about half the eu market as a second- and third-line therapy. But celgene has put revlimid ...
- Industries: Pathology
- Countries: United States
U.S. Drug and Medication Business Brief
- Industry report
- February 2012
- 19 pages
- by Corporation
... Patients (aged 65 Years) filed claims for mds in 2003 * * source: cyclacel est. &Amp; golberg, s, et al, jco, 2010. Revlimid , celgene. # Vidaza , celgene. &Amp; dacogen , eisai. Dacogen and vidaza ...
- Industries: Drug and Medication
- Countries: United States
World Clinical Laboratory Business Brief
- Industry report
- January 2011
- 4 pages
... celgene partnering 2005-2012 cephalon partnering 2005-2012 chugai partnering 2005-2012 csl partnering 2005-2012 daiichi sankyo partnering 2005-2012 dainippon sumitomo partnering 2005 ...
- Industries: Diagnostics
- Countries: World
Drug and Medication Sector in The United States
- Industry report
- October 2012
- 22 pages
- by Corporation
... Revlimid , celgene. Vidaza , celgene. &Amp; dacogen , eisai. Dacogen and vidaza are hypomethylating(hm) agents. Nccn guidelinesmds v.2.2011P. 19. Prebett, gore s, et al,jco 2011; jabbour ...
- Industries: Drug and Medication
- Countries: United States
Drug and Medication Market in Canada
- Industry report
- January 2011
- 27 pages
- by Governmental Agency
... Matter board resolution judicial review celgene corporation and thalomid Board confirms jurisdiction: sales from us to canada under health canada S special access programme Supreme ...
- Industries: Drug and Medication
- Countries: Canada
Cancer in The United States and Switzerland : Innovation and Technology Trends
- Industry report
- January 2013
- 16 pages
... Above $100m (2007-2012) selected exits of nextech invest 2007 2008 2009 2011 2012 buyer: astellas $512m buyer: ats n/a buyer: celgene $640m buyer: daiichi sankyo $805m buyer: celgene $925m public ...
- Industries: Pathology
- Countries: United States, Switzerland
Biological Therapy in Austria : Innovation and Technology Trends
- Industry report
- January 2011
- 16 pages
... Covidien.Com celgene cellular therapeutics celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. celgene S mission as a company is to build a major global ...
- Industries: Biological Therapy
- Countries: Austria, World
Biological Therapy : Innovation and Technology Trends
- Industry report
- January 2011
- 9 pages
... Therapeutics celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. celgene S mission as a company is to build a major global biopharmaceutical corporation while ...
- Industries: Biological Therapy
Medicine Sector in Canada
- Industry report
- January 2012
- 10 pages
- by Governmental Agency
... Is to make a payment in the amount of $10,000,000 to the government of canada no later than february 20, 2012, in order to comply with the guidelines. celgene will also ensure that the average transaction ...
- Industries: Drug and Medication
- Countries: Canada
Reportlinker.com © Copyright 2013. All rights reserved.
